Request a Quote

Cyprotex Highlights - February 2022

2022 Header

We are excited to announce our new immunotoxicity service; the peripheral blood mononuclear cell (PBMC) cytotoxicity assay. This service assesses the cytotoxic potential of candidate drugs towards PBMC and can be followed up with a variety of further studies with additional endpoints, offering further insights into the mechanisms of drug-mediated hypersensitivity.

Read more about PBMC cytotoxicity

We also have several other services in development to assist with the prediction of immunotoxicity in early drug development. Find out more about this area by clicking the link below, or contact us to make an enquiry:

Read more about immunotoxicology

Contact us

Our latest blog, “Oral Dose Pharmacokinetic Profiling for Early Drug Discovery”, explores the most recent additions to our PK prediction services. Click below to find out more, or watch the webinar to learn more about our work in using ADME data to predict human PK parameters.

Read the blog

Watch the webinar

Next month, March 27-31, Cyprotex and parent company Evotec will be exhibiting at the 61st Annual Society of Toxicology Meeting (SOT) in San Diego.

Here you can find us at booth number 1226 where our team will be on hand to discuss our latest research and how we can help you with your projects. Get in touch to book a meeting:

Meet us at SOT

We have a variety of posters to share, covering neuro-, cardio-, and immunotoxicology, as well as our latest advances in transcriptomics.

In addition, we will be hosting a seminar presented by Paul Walker, PhD (VP, Head of Toxicology).

Find out more and request your copies of the posters and slide deck by exploring our SOT event page:

Find out more

Read the latest news from parent company, Evotec:

  • Evotec invests in sustainability at Dorothy Crowfoot Hodgkin Campus site to reduce CO2 emissions and work towards carbon neutral targets
  • Evotec invests in IMIDomics, Inc. to support discovery and development of immune-mediated inflammatory disease treatments
  • Evotec invests in Centauri Therapeutics Limited Series A investment round to further the treatment of infectious diseases

Read the press releases

Read more from Evotec, Cyprotex and Just - Evotec Biologics in the Science Pool blog:

Read the blog

Contact us


Contact us to discuss your ADME Tox issues or request a quote

Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683

or fill out the form below:


Download file